Archive

2019

• InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
• InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
• InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting
• InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

2018

• New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology
• InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting
• InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
• InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

2017

• New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program

2016

• InteRNA builds Management Team for next stage of development

2015

• InteRNA Technologies secures final extension Series A financing and strengthens its Supervisory Board

2014

• InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease

2013

• InteRNA's R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen
• SomantiX B.V. and InteRNA Technologies B.V. obtain a MIT R&D collaboration grant
• InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia
• InteRNA Technologies partner in €11.5 Million EU Framework Program 7
• MiRacle Consortium led by InteRNA Technologies and VU University Medical Center

2012

• InteRNA Technologies B.V. announces full consolidation of its subsidiary InteRNA Genomics B.V. as of July 1, 2012
• InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product

2011

• InteRNA Technologies Strengthens its R&D Team Nijmegen/Utrecht (the Netherlands)
• Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
• InteRNA Technologies announces establishment of Supervisory Board

2010

• InteRNA Technologies announces establishment of Scientific Advisory Board Utrecht (the Netherlands)
• InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands)

2009

• InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
• New small and medium enterprises join TIPharma by signing two new projects
• InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

2008

• InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer
• InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing
• InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery